Table 3.
Efficacy at 2 yr in HBeAg positive and HBeAg negative individuals in the Globe study receiving Telbivudine or lamivudine
| Telbivudine | Lamivudine | P value | |
| HBeAg positive patients | |||
| HBV DNA fall (mean log10) | -5.7 | -4.4 | < 0.05 |
| HBV DNA non-detectable by PCR (%) | 54 | 38 | < 0.05 |
| Treatment failure (%)1 | 4 | 12.3 | < 0.05 |
| HBeAg negative patients | |||
| HBV DNA fall (mean log10) | -5 | -4.2 | < 0.05 |
| HBV DNA non-detectable by PCR (%) | 79 | 53 | < 0.05 |
| Treatment failure (%)1 | 0 | 3 | < 0.05 |
1
Defined as HBV DNA > 5 log10 copies/mL.